Clinical Trials
3 trialsNCT03123393 2023-02-08
TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Calithera Biosciences, Inc
Phase 2 Terminated
NCT03238651 2023-02-08
A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)
Calithera Biosciences, Inc
Phase 1 Terminated
NCT02954406 2022-02-18
A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
Takeda
Phase 1 Terminated